Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

lktlabs.com Web:

Product Information

Product ID N0123 CAS No. 57149-07-2

Chemical Name

Synonym

Formula $C_{24}H_{28}N_2O_3$ Formula Wt. 392.49 Melting Point 209.0 - 212.0

> Purity ≥98% Solubility

OH

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
N0123	25 mg	\$126.50
N0123	100 mg	\$408.50
N0123	500 mg	\$1080.50

Store Temp Ambient Ship Temp Ambient

Description Naftopidil is an inhibitor of α1-adrenergic receptors that is clinically used to improve lower urinary tract symptoms in subjects with benign prostatic hyperplasia (BPH). In clinical trials, naftopidil improves nocturnal polyuria. Naftopidil improves bladder capacity through both its effect on adrenergic signaling as well as inhibition of c-fiber afferent nerves. Additionally, this compound inhibits

collagen-induced Ca2+ mobilization and platelet aggregation in vitro, exhibiting potential anti-platelet benefit.

References Castiglione F, Benigni F, Briganti A, et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Curr Med Res Opin. 2013 Dec 18. [Epub ahead of print]. PMID: 24188134.

> Yokoyama O, Aoki Y, Tsujimura A, et al. α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume. World J Urol. 2011 Apr;29(2):233-8. PMID: 20387069.

Yokoyama O, Yusup A, Oyama N, et al. Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn. 2006;25(5):461-7. PMID: 16673377.

Alarayyed NA, Cooper MB, Prichard BN, et al. In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Br J Clin Pharmacol. 1997 Apr;43(4):415-20. PMID: 9146854.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.